MedPath
Found 16 clinical trials|View Analysis
Sort by:

Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Phase 3
Recruiting
Conditions
Myelofibrosis
Post-ET Myelofibrosis
Primary Myelofibrosis
Post-PV MF
MF
Interventions
First Posted Date
2024-06-28
Last Posted Date
2024-12-24
Lead Sponsor
Kartos Therapeutics, Inc.
Target Recruit Count
600
Registration Number
NCT06479135
Locations
🇦🇺

St George Hospital, Kogarah, Australia

🇺🇸

Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States

🇺🇸

Medical Oncology Hematology Consultants, PA, Newark, Delaware, United States

and more 76 locations

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Phase 2
Recruiting
Conditions
Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-Essential Thrombocytosis Myelofibrosis
Interventions
First Posted Date
2024-03-25
Last Posted Date
2024-08-05
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
33
Registration Number
NCT06327100
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Phase 1
Recruiting
Conditions
Myelofibrosis
Post-ET Myelofibrosis
Post-PV MF
Primary Myelofibrosis
Interventions
Drug: TL-895
Drug: Ruxolitinib
First Posted Date
2022-03-15
Last Posted Date
2023-02-21
Lead Sponsor
Telios Pharma, Inc.
Target Recruit Count
70
Registration Number
NCT05280509
Locations
🇮🇹

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy

🇮🇹

Azienda Ospedaliera di Perugia-Ospedale S. Maria della Misericordia, Perugia, Italy

🇪🇸

Hospital Quironsalud de Zaragoza, Zaragoza, Spain

and more 16 locations

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Phase 2
Recruiting
Conditions
Primary Myelofibrosis (PMF)
Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)
Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
Interventions
Drug: TL-895
Drug: KRT-232
First Posted Date
2021-05-07
Last Posted Date
2022-05-09
Lead Sponsor
Kartos Therapeutics, Inc.
Target Recruit Count
52
Registration Number
NCT04878003
Locations
🇺🇸

Innovative Clinical Research Institute, Whittier, California, United States

🇺🇦

City Hematology Center of Municipal Non-Profit Enterprise City Clinical Hospital #4 of Dnipro City Council, Dnipro, Ukraine

🇧🇾

Minsk Scientific and Practice Center of Surgery, Transplantology and Hematology, Minsk, Belarus

and more 25 locations

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Phase 1
Recruiting
Conditions
Primary Myelofibrosis
Post-ET Myelofibrosis
Myelofibrosis
Post-PV MF
Interventions
Drug: KRT-232
Drug: TL-895
First Posted Date
2020-11-23
Last Posted Date
2022-05-09
Lead Sponsor
Kartos Therapeutics, Inc.
Target Recruit Count
116
Registration Number
NCT04640532
Locations
🇫🇷

CHU Nantes - Hôtel Dieu, Nantes, France

🇭🇺

Medical Center of the University of Pecs, 1st Department of Internal Medicine, Division of Hematology, Pécs, Hungary

🇵🇱

Nasz Lekarz Medical Outpatient Clinics Slawomir Jeka, Toruń, Poland

and more 34 locations

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Phase 1
Recruiting
Conditions
Myelofibrosis
Interventions
Drug: KRT-232
Drug: Ruxolitinib
First Posted Date
2020-07-24
Last Posted Date
2022-05-09
Lead Sponsor
Kartos Therapeutics, Inc.
Target Recruit Count
36
Registration Number
NCT04485260
Locations
🇫🇷

Institut Paoli-Calmettes, Marseille, France

🇵🇱

Oddział Kliniczny Hematologii Szpitala Uniwersyteckiego w Krakowie, Kraków, Poland

🇵🇱

Szpital Wojewódzki w Opolu Sp zooOddzial Kliniczny Hematologii, Opole, Poland

and more 35 locations

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Phase 1
Active, not recruiting
Conditions
Primary Myelofibrosis
Interventions
First Posted Date
2020-06-25
Last Posted Date
2024-09-30
Lead Sponsor
Celgene
Target Recruit Count
31
Registration Number
NCT04446650
Locations
🇯🇵

Local Institution - 016, Osaka, Japan

🇯🇵

Local Institution - 014, Sapporo, Japan

🇯🇵

Local Institution - 021, Suwa, Nagano, Japan

and more 18 locations

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Phase 2
Completed
Conditions
Primary Myelofibrosis (PMF)
Post-polycythemia Vera Myelofibrosis(Post-PV MF)
Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Interventions
First Posted Date
2020-01-06
Last Posted Date
2023-04-20
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
51
Registration Number
NCT04217993
Locations
🇨🇳

The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Phase 1
Terminated
Conditions
Post-Polycythemia Vera Myelofibrosis (Post-PV MF)
Primary Myelofibrosis (PMF)
Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
Drug: PU-H71
First Posted Date
2019-05-02
Last Posted Date
2022-11-17
Lead Sponsor
Samus Therapeutics, Inc.
Target Recruit Count
11
Registration Number
NCT03935555
Locations
🇺🇸

Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

🇺🇸

Marin Cancer Care - Greenbrae (California Cancer Care A Medical Group, Inc. - Greenbrae), Larkspur, California, United States

🇺🇸

MD Anderson, Houston, Texas, United States

MPN-RC 118 AVID200 in Myelofibrosis

Phase 1
Completed
Conditions
Post-polycythemia Vera Myelofibrosis
Post PV MF
Primary Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Post ET MF
Interventions
Drug: AVID200
First Posted Date
2019-03-29
Last Posted Date
2023-02-10
Lead Sponsor
John Mascarenhas
Target Recruit Count
21
Registration Number
NCT03895112
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath